Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 255-259

  Aydin, K ^a   Okutur, S K ^a   Bozkurt, M ^a   Turkmen, I ^a   Namal, E ^a   Pilanci, K ^a   Ozturk, A ^a   Akcali, Z ^a   Dogusoy, G ^b   Demir, O G ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

Author keywords

Epidermal growth factor receptor; Gastric cancer; Prognosis

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; UFT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVARY METASTASIS; PERINEURAL INVASION; PILOT STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR NECROSIS;

EID: 84888411517     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1662     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
3. Al-Batran SE, Hartmann JT, Hofheinz R, et al: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19: 1882-1887, 2008.
4. Cunningham D, Okines AF and Ashley S: Capecitabine and oxaliplatin for advanced esophagogastric cancer: N Engl J Med 362: 858-859, 2010.
5. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
6. Voldborg BR, Damstrup L, Spang-Thomsen M and Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8: 1197-1206, 1997.
7. Nicholsan RI, Gee JM and Harper ME. EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4: S9-S15, 2001.
8. Yonemura Y, Sugiyama K, Fujimara T, Kamata T, Fushida S, Yamaguchi A, et al: Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology 46: 158-161, 1989.
9. Jang WI, Yang WI, Lee CI, Kim HS, Song KS, Cho MY, Park JK and Shim YH: Immunohistochemical detection of p53 protein, c-erbB-2 protein, epidermal growth factor receptor protein and proliferating cell nuclear antigen in gastric carcinoma. J Korean Med Sci 8: 293-304, 1993.
10. García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P and García-Muñiz JL: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10: 234-241, 2003.
11. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F and Ferraraccio F: Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31: 1458-1468, 2007.
12. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, Busch R, Hermannstädter C, Nährig J, Becker KF, Becker I, Höfler H, Fend F and Luber B: Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 17: 579-587, 2004.
13. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F and Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15: 69-79, 2008.
14. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52: 738-746, 2008.
15. Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y and Shimoda T: Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 74: 76-83, 2008.
16. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Sano T, Imamura H and Sasako M; ACTS-GC Group: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in patients with stage II/III gastric cancer. Clin Cancer Res 18: 5992-6000, 2012
17. Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ and Kim NK: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 100: 732-738, 2009.
18. Ye YW, Dong RZ, Zhou Y, Du CY, Wang CM, Fu H and Shi YQ. Prognostic analysis of familial gastric cancer in Chinese population: J Surg Oncol 104: 76-82, 2011.
19. Atmaca A, Werner D, Pauligk C, Steinmetz K, Wirtz R, Altmannsberger HM, Jäger E and Al-Batran SE: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 12: 524, 2012.
20. Song HS, Do YR, Kim IH, Sohn SS and Kwon KY: Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat 36: 240-245, 2004.